Summary:
A 12-week, randomized, double blind, placebo controlled study of a new therapy in subjects with irritable bowel syndrome.
Qualified Participants Must:
Have been diagnosed with Irritable Bowel Syndrome
Be willing to comply with the study protocol
Qualified Participants May Receive:
Compensation, free Study Medication and free study related healthcare.